Opsin-Binding Ligands, Compositions and Methods of Use

Inactive Publication Date: 2015-02-05
BIKAM PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020]Mislocalization of photoreceptor cell visual pigment proteins (opsins) can occur in various ocular diseases, and also with normal aging. In such cases the accumulation of mislocalized opsin leads to the decline in viability of photoreceptor cells. With time this mislocalized opsin accumulation leads to rod and cone cell death, retinal degeneration, and loss of vision. In one aspect, the invention provides a method of correcting mislocalized opsin within a photoreceptor cell, comprising contacting a mislocalized opsin protein with an opsin-binding agent that binds reversibly and/or non-covalently to said mislocalized opsin protein to promote the appropriate intracellular processing and transport of said opsin protein. This correction of mislocalization reduces photoreceptor cell stress, preventing photoreceptor cell decline in viability and death in various diseases of vision loss, and in normal age-related decline in dim-light and peripheral rod-mediated vision, central cone-mediated vision, and loss of night vision.

Problems solved by technology

A number of visual, ophthalmic, problems can arise due to interference with this cycle.
It is now understood that at least some of these problems are due to improper protein folding, such as that of the protein opsin.
In some cases, such as due to genetic defects and mutation of the opsin protein, opsin can exhibit improper folding to form a conformation that either fails to properly insert into the membrane of the rod cell or else inserts but then fails to properly react with 11-cis-retinal to form native rhodopsin.
In either case, the result is moderate to severe interference with visual perception in the animal so afflicted.
In RP, photoreceptor cells in the retina are damaged or destroyed, leading to loss of peripheral vision (i.e., tunnel vision) and subsequent partial or near-total blindness.
The aggregation of the misfolded protein is believed to result in photoreceptor damage and cell death.
These are not very desirable for treating ophthalmic disease because such treatment usually requires high dosages that may cause toxic side effects.
A2E can also prove toxic to the RPE and has been associated with dry ARMD.
However, during surgical procedures on the eye, especially on the retina, where strong light is required over an extended period, for example, near the end of cataract surgery and while implanting the new lens, these otherwise natural processes can cause toxicity because of the build-up of natural products of the visual cycle.
Additionally, excessive rhodopsin activation as a result of bright light stimulation can cause photoreceptor cell apoptosis via an AP-1 transcription factor dependent mechanism.
Because of this, there is a need for agents that can be administered prior to, during or after (or any combination of these) the surgical process and that has the effect of inhibiting rhodopsin activation as well as reducing the production of visual cycle products that would otherwise accumulate and result in toxicity to the eye, especially to the retina.
Importantly, such agents are not natural retinoids and thus are not tightly controlled for entrance into the rod cells, where mutated forms of opsin are synthesized and/or visual cycle products otherwise accumulate.
In both cases the accumulation of mislocalized opsin leads to the decline in viability of photoreceptor cells.
With time this mislocalized opsin accumulation leads to rod and cone cell death, retinal degeneration, and loss of vision.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Opsin-Binding Ligands, Compositions and Methods of Use
  • Opsin-Binding Ligands, Compositions and Methods of Use
  • Opsin-Binding Ligands, Compositions and Methods of Use

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1

3-(trifluoromethyl)-N-((2,6,6-trimethylcyclohex-1-enyl)methyl)aniline hydrochloride

Example

Example 1a

3-(trifluoromethyl)-N-((2,6,6-trimethylcyclohex-1-enyl)methyl)aniline

[0420]To a stirred solution of 2,6,6-trimethylcyclohex-1-enecarbaldehyde (152 mg, 1.0 mmol) in methanol (3 mL) was added 3-(trifluoromethyl)aniline (161 mg, 1.0 mmol). To the stirred mixture was added acetic acid (0.1 mL) followed by sodium cyanborohydride (188 mg, 3.0 mmol). The reaction was stirred at room temperature for 3 hours and then the reaction was quenched by addition of saturated aqueous ammonium chloride (5 mL). The methanol was evaporated under reduced pressure and the residue was diluted with ethyl acetate (40 mL). The organic phase was washed with water (30 mL×2) and brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silca gel column chromatography (eluent: petroleum ether / ethyl acetate=100 / 1) to afford the title compound as a colorless oil (200 mg, Yield: 67%). Rf=0.8 (30:1 petroleum ether / ethyl acetate); 1H NMR (400 M

Example

Example 2

3-methyl-N-((2,6,6-trimethylcyclohex-1-enyl)methyl)aniline

[0422]To a stirred solution of 2,6,6-trimethylcyclohex-1-enecarbaldehyde (152 mg, 1.0 mmol) in methanol (3 mL) was added m-toluidine (107 mg, 1.0 mmol), acetic acid (0.1 mL) followed by sodium cyanoborhydride (187 mg, 3.0 mmol). The reaction was stirred at room temperature for 1 hour and then was quenched by addition of saturated aqueous ammonium chloride (5 mL). The methanol was evaporated under reduced pressure and the residue was diluted with ethyl acetate (40 mL). The organic phase was washed with water (30 mL×2) and brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate=100 / 1) to afford the title compound as a colorless oil (185 mg, Yield: 76%). Rf=0.7 (20:1 petroleum ether / ethyl acetate); 1H NMR (400 MHz, CDCl3) δ 7.09-7.05 (m, 1H), 6.50 (d, J=7.2 Hz, 1H), 6.42 (s, 1H), 6.4

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Electrical conductanceaaaaaaaaaa
Toxicityaaaaaaaaaa
Login to view more

Abstract

Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner BIKAM PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products